Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy

被引：26

作者：

Bahrami, Afsane ^{[1
,2
]}

Amerizadeh, Forouzan ^{[1
,2
]}

Hassanian, Seyed Mahdi ^{[3
,4
]}

ShahidSales, Soodabeh ^{[5
]}

Khazaei, Majid ^{[6
]}

Maftouh, Mina ^{[3
]}

Ghayour-Mobarhan, Majid ^{[3
]}

Ferns, Gordon A. ^{[7
]}

Avan, Amir ^{[3
]}

机构：

[1] Mashhad Univ Med Sci, Fac Med, Dept Modern Sci & Technol, Mashhad, Iran

[2] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Iran

[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[4] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran

[5] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran

[6] Mashhad Univ Med Sci, Fac Med, Dept Physiol, Mashhad, Iran

[7] Brighton & Sussex Med Sch, Div Med Educ, Brighton, Sussex, England

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2018年 / 233卷 / 03期

关键词：

colorectal cancer; oxaliplatin; predictive biomarkers; resistance; DNA-REPAIR GENES; GLUTATHIONE-S-TRANSFERASE; GROWTH-FACTOR-RECEPTOR; MICROSATELLITE INSTABILITY; ADJUVANT CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; THERAPEUTIC PROGNOSIS; FOLFOX-4; CHEMOTHERAPY; CISPLATIN RESISTANCE; CHINESE POPULATION;

D O I：

10.1002/jcp.25966

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Chemotherapy regimen containing oxaliplatin is often the first-line treatment for patient with advanced colorectal cancer. Oxaliplatin binds to DNA, leading to the formation of crosslinks and bulky adducts. Approximately 50% of patients with CRC benefit from treatment with oxaliplatin. It is possible that genetic variants in biological pathways involved in drug transportation, drug metabolism, DNA damage repair, and cell cycle modulation might affect the activity, or efficacy of oxaliplatin. Because oxaliplatin resistance may be related to these genetic variants and may therefore be an important reason for treatment failure, we have summarized the genetic variations that have been reported to be predictive markers of the response to oxaliplatin based therapy in patients with advanced CRC.

引用

页码：2193 / 2201

页数：9

共 50 条

[31] phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
Kotaka, M.
Ishibashi, K.
Satake, H.
Tsuji, Y.
Kataoka, M.
Nakamura, M.
Nagata, N.
Sakamoto, J.
Oba, K.
Mishima, H.
ANNALS OF ONCOLOGY, 2020, 31 : S101 - S101
[32] Oxaliplatin-based Chemotherapy in Patients Aged 75 Years or Older with Metastatic Colorectal Cancer
Fukuchi, Minoru
Ishibashi, Keiichiro
Tajima, Yusuke
Okada, Norimichi
Yokoyama, Masaru
Chika, Noriyasu
Hatano, Satoshi
Matsuzawa, Takeaki
Kumamoto, Kensuke
Kumagai, Youichi
Baba, Hiroyuki
Mochiki, Erito
Ishida, Hideyuki
ANTICANCER RESEARCH, 2013, 33 (10) : 4627 - 4630
[33] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
Keiichiro Ishibashi
Toru Aoyama
Masahito Kotaka
Hironaga Satake
Yasushi Tsuji
Masato Kataoka
Masato Nakamura
Naoki Nagata
Junichi Sakamoto
Koji Oba
Hideyuki Mishima
Cancer Chemotherapy and Pharmacology, 2021, 87 : 665 - 672
[34] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
Ishibashi, Keiichiro
Aoyama, Toru
Kotaka, Masahito
Satake, Hironaga
Tsuji, Yasushi
Kataoka, Masato
Nakamura, Masato
Nagata, Naoki
Sakamoto, Junichi
Oba, Koji
Mishima, Hideyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 665 - 672
[35] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
Tada, K.
Shoji, H.
Kitano, S.
Nishimura, T.
Shimada, Y.
Nagashima, K.
Ito, A.
Honma, Y.
Iwasa, S.
Okita, N.
Takashima, A.
Kato, K.
Yamada, Y.
Katayama, N.
Boku, N.
Heike, Y.
Hamaguchi, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
[36] The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system
Dermitzakis, E. V.
Kimiskidis, V. K.
Eleftheraki, A.
Lazaridis, G.
Konstantis, A.
Basdanis, G.
Tsiptsios, I.
Georgiadis, G.
Fountzilas, G.
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (12) : 1471 - 1477
[37] RETRACTED: Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer (Retracted Article)
Lv, Hongying
Li, Qicai
Qiu, Wengsheng
Xiang, Jinyu
Wei, Hongjun
Liang, Hua
Sui, Aihua
Liang, Jun
CANCER INVESTIGATION, 2013, 31 (01) : 24 - 28
[38] Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer
Fleishman, Stewart B.
Mahajan, Divya
Rosenwald, Victoria
Nugent, Ann V.
Mirzoyev, Tahir
JOURNAL OF ONCOLOGY PRACTICE, 2012, 8 (03) : 136 - 140
[39] Oxaliplatin-Based Chemotherapy for Colon Cancer
Bonetti, Andrea
Furini, Lara
PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY: MOLECULAR MECHANISMS AND CLINICAL APPLICATIONS, 2009, : 271 - 284
[40] Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy
Kaneko, Manabu
Nozawa, Hiroaki
Sasaki, Kazuhito
Hongo, Kumiko
Hiyoshi, Masaya
Tada, Noriko
Murono, Koji
Nirei, Takako
Kawai, Kazushige
Sunami, Eiji
Tsuno, Nelson H.
Kitayama, Joji
ONCOLOGY, 2012, 82 (05) : 261 - 268

← 1 2 3 4 5 →